remain about the role of central obesity in predicting atherosclerotic CVD (ASCVD) in older adults. This is an important issue given the global obesity epidemic and an increasingly aging population.
In this issue of the Journal of the American Heart Association (JAHA), Schousboe et al examine associations of central adiposity and incident ASCVD in the study of MrOS Sleep (Outcomes of Sleep Disorders in Older Men), an ancillary to the study of MrOS (Osteoporotic Fractures in Men). 8 MrOS Sleep is a large, epidemiologic cohort of older white men with comprehensively measured and adjudicated ASCVD outcomes. The ability to comprehensively assess and evaluate central obesity as a predictor of ASCVD outcomes in a large study of older adults is uncommon, and to our knowledge, this is only the second study to do so. Schousboe et al 8 found no significant associations between visceral adipose tissue or android-gynoid fat mass ratio and ASCVD; and this finding persisted in the subset of their cohort who did not have comorbid conditions and the subset who were overweight or normal weight. The null and paradoxical findings of this study leave us grappling with the clinical and public health implications of developing and/or maintaining higher levels of central adiposity over the life course. Although the MrOS Sleep study data set is a rich resource within which to examine the relationship between central obesity and incident ASCVD, as with all epidemiologic cohorts with data for older adults, there are complexities and potential biases that may be exacerbated in this context. Schousboe et al acknowledged concerns, such as their inability to use computed tomography or magnetic resonance imaging to measure visceral adipose tissue and the unavailability of medical records to confirm the self-reported health conditions of participants at study baseline. Additional biases that influence these types of analyses include measurement error, collider stratification bias (the "obesity paradox"), and reverse causality.
With regard to measurement error, the increasing use of direct measurements of central obesity, as done by Schousboe et al 8 with dual-energy x-ray absorptiometry for visceral adipose tissue, helps to minimize the concerns that emerge when proxy measures, such as body mass index, are used in obesity research ( Figure) . A contemporary approach is the concordant measurement and analysis of subcutaneous fat and lean mass, which allows for better understanding of the underlying cause of CVD in older adults. Widespread utility of concordant measures in observational epidemiologic studies is limited by cost and the participant burden associated with multiple in-clinic visits and imaging. Collider stratification bias (Figure) is a distinctive form of selection bias that may account for the paradoxical findings that were observed. 9 This bias emerges from the fact that to participate in a study of central adiposity at ≥70 years, it is necessary to have survived to older age and to have preserved physical and cognitive function. Few Americans are truly free of cardiometabolic disease at the age of 70 years, and this
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population has already experienced multiple selective survival pressures that can result in biased estimates. Because of this, some have suggested that the obesity paradox does not exist and the relationship of adiposity to CVD should be addressed entirely in the context of unmitigated bias. 10 It has even been argued that journals should reject all "future studies on the obesity paradox that fall into the collider bias trap."
11
In all studies of individuals above a certain age or where mortality is the study outcome, reverse causality is a serious concern (Figure) because unmeasured or subclinical disease can result in weight loss or decreased central obesity. This subclinical disease affects the likelihood of the outcome being studied and can bias study estimates of associations. There is increasing evidence of a relationship between adiposity and noncardiometabolic outcomes, such as some cancers, cognitive function, and physical disability. This increases the possibility of conflating intentional weight loss (or reduction in adiposity) with the consequences of unintentional weight loss (or reduction in adiposity). Solutions include beginning follow-up at younger ages and excluding the 5 years of follow-up that are adjacent to the time that measurements of adiposity were taken. Doing so would change the focus of this field away from evaluating whether central adiposity after the age of 70 years results in ASCVD in the next 5 to 10 years, toward how to best intervene on excess adiposity over the life course to prevent ASCVD in this age group. The process and consequences of developing obesity as an older adult are likely to differ from those of developing obesity earlier in life. Although the MrOS Sleep study is a longitudinal cohort, it can only provide a snapshot of exposure to central obesity and resulting outcomes, so the challenge to understand the cardiovascular consequences of cumulative exposure to central obesity remains.
A possible misinterpretation of the findings from the study by Schousboe et al 8 is that central adiposity does not confer cardiovascular risk and that peripheral adiposity may even be beneficial. The investigators report a significant inverse association between ASCVD and gynoid fat mass (presumably containing a preponderance of subcutaneous fat). Although consistent with studies examining hip circumference and other proxy measures of fat mass traditionally differentiated by sex, the findings from the analyses of the MrOS Sleep study could generate 2 opposing hypotheses: first, subcutaneous fat, itself, is protective against cardiometabolic dysfunction 12 ; and second, the ability to store excess fat in the subcutaneous compartment instead of in the body cavity and in and around the organs mitigates the pathological condition of excess adiposity. 13 This second hypothesis suggests that it is not total subcutaneous fat volume, but how much capacity there is to store fat in the subcutaneous depot, that explains both differences in the relationship between visceral and subcutaneous fat with CVD, and potentially the sex differences in CVD risk. To date, subcutaneous fat has not been found to be associated with incident CVD after the impact of visceral fat has been accounted for. [1] [2] [3] [4] New research findings in both the clinical and basic science realms present growing support for the importance of subcutaneous capacity, 14, 15 and offer additional reminders to exercise caution when ascribing "cause or consequence." This study in older white men may not be generalizable to other populations (eg, some Asians), who at apparently normal weight, as determined by their body mass index, have excessive visceral fat and higher risks for cardiometabolic diseases. 16 Efforts to prevent central obesity through healthy lifestyles seem prudent for all.
No one study can address all methodologic issues, and despite the complexities inherent to this licne of research, the analyses conducted by Schousboe et al 8 extend our thinking about this important health issue. Their findings beg the question as to what should be the health priority for adults older than 70 years? Is the priority to extend life by preventing the cardiovascular consequences of central adiposity? Or is the priority to prolong quality of life? And, are there competing conditions that are more likely to affect life expectancy and quality of life, making the focus on primary prevention of CVD less important? It is still unknown whether the ability to retain or accumulate fat mass in older adulthood is a marker of resilience in aging and the absence of disease. It is exceptionally challenging to disentangle the multiple potential sources of potential bias in observational epidemiologic studies of central obesity and ASCVD in older adults.
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